HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Malignant hyperthermia susceptibility type 5

Also Known As:

Malignant hyperpyrexia susceptibility type 5

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Signs and Symptoms Pathological Conditions
- Pathologic Processes: 10023
  - Intraoperative Complications: 3522
    - Malignant Hyperthermia: 2449
      - Malignant hyperthermia susceptibility type 5: 1
  - Postoperative Complications
    - Malignant Hyperthermia: 2449
      - Malignant hyperthermia susceptibility type 5: 1
- Signs and Symptoms
  - Body Temperature Changes: 152
    - Hyperthermia: 14068
      - Malignant Hyperthermia: 2449
        Malignant hyperthermia susceptibility type 5: 1

Experts

1.	Beam, Teresa A: 1 article (01/2017)
2.	Kisor, David F: 1 article (01/2017)
3.	Loudermilk, Emily F: 1 article (01/2017)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Malignant hyperthermia susceptibility type 5:

1.	CalciumIBA 01/01/2017 - "A review of the pharmacogenetics (PGt) and pathophysiology of calcium voltage-gated channel subunit alpha1 S (CACNA1S) mutations in malignant hyperthermia susceptibility type 5 (MHS5; MIM #60188) is presented. "